Every superannuation calculator throws a different number at you. A million dollars. Two million. $630,000.

It’s enough to make anyone give up and spend the lot on a campervan instead. So let’s cut through the noise and answer one specific, useful question: how much superannuation do you actually need to retire on $50,000 a year?

The benchmark everyone quotes

The Association of Superannuation Funds of Australia (ASFA) publishes the go-to guide for retirement adequacy in this country. A comfortable retirement standard sits at $55,923 a year for a single person and $78,566 for a couple. The modest standard is much lower, at $36,434 and $52,473 respectively.

A $50,000 income, then, sits right in the gap — comfortably above modest, just shy of comfortable. That’s not a bad place for your superannuation to land.

What lump sum actually gets you there?

A single homeowner is estimated to need a superannuation lump sum of $630,000 to fund a comfortable retirement, while a couple needs $730,000.

Since $50,000 sits below the comfortable threshold, you’re likely looking at something meaningfully under $630,000 in superannuation. Think mid-to-high $500,000s for a single homeowner, depending on your drawdown strategy and how much Age Pension support you pick up along the way.

Crucially, those superannuation figures assume a 6% investment return alongside some Age Pension support — this isn’t a “live off $630,000 with zero government help” scenario. The pension is baked into the maths, not a fallback you’re meant to avoid.

The self-funded reality check

Here’s where it gets sharper. Once your superannuation converts to an account-based pension, the government sets minimum withdrawal rates. For anyone aged 65 to 74, that minimum is 5% of the balance each year.

Run that in reverse, and a $50,000 target implies a superannuation balance of roughly $1 million if you’re funding it entirely yourself, with zero pension support. That’s the sobering, no-safety-net version of the number.

So which is it: $600,000 or $1 million?

Both are correct. It just depends on your plan. Are you relying on the Age Pension, or going it entirely alone with your superannuation?

Most Australians land somewhere in between. A part pension top-up can stretch a sub-$700,000 superannuation balance much further than the raw maths would suggest.

Where do you actually sit?

Average superannuation balances for Australians aged 65-69 sit at roughly $448,518 for men and $392,274 for women. That’s short of the comfortable benchmark for most singles, but not miles off a $50,000-a-year lifestyle once the pension is factored in.

Foolish takeaway

There’s no single magic superannuation number for ‘enough’. A sum of $50,000 a year is achievable on a balance well under $630,000 if the Age Pension does some of the heavy lifting. Or it demands close to $1 million in superannuation if you’re determined to self-fund every dollar.

The real question isn’t “how much superannuation do I need?” It’s “how much of my retirement am I willing to hand over to the government to top up?” Answer that first, and the number gets a lot easier to find.

The post How much superannuation is enough to retire with a $50,000 income? appeared first on The Motley Fool Australia.

More reading

• Want the age pension? Here’s the new asset limit you can’t exceed
• Here are the top 10 ASX 200 shares today
• The ASX 200 is finally rising. Is the sell-off running out of steam?
• 5 things to watch on the ASX 200 on Wednesday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

RBC Capital Markets has released a new report on the Australian-listed healthcare sector, upgrading five major stocks to an outperform rating in the process.

The broking house said healthcare had performed “generally much better than we had feared” across the August reporting season.

They added:

A combination of revenue beats and cost control drove earnings beats for most companies and we are now expecting positive earnings growth across the sector. While most of the sector has enjoyed a re-rating over the past 2 months, we believe a number of stocks could re-rate even further given their earnings growth outlook, appealing relative valuations and attractiveness of the healthcare sector in light of macroeconomic uncertainty.

As a result of this positivity, RBC has upgraded five stocks to an outperform rating and maintained that rating on one more.

Let’s see who they like.

CSL Ltd (ASX: CSL)

RBC said the recent result showed that CSL was regaining market share in the key immunoglobulin sector.

The broker said they now believed that “growth in the Behring business can offset the weak outlook in the Seqirus and Vifor business, and enable the company to deliver mid-single digit EPS growth for the next 3 years”.

While these growth rates were below historical levels, RBC said they were reasonable compared to other Australian large-cap stocks.

RBC has a price target of $213 on CSL shares.

Resmed Ltd (ASX: RMD)

The sleep apnoea device company delivered an in-line result, RBC said; however, there was more focus on capital management.

The broker is factoring in $1.5 billion in share buybacks per year out to FY31.

RBC has a price target of $262 on Resmed shares.

Ramsay Healthcare Ltd (ASX: RHC)

RBC said Ramsay was being well run, with its recent result showing good revenue growth and cost control.

They have valued the company on a demerger basis and believe such a strategy would create value.

RBC has a price target of $68 on Ramsay shares.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

RBC said this company’s trading update revealed a strong start to the year and an upgrade to FY27 guidance.

The broker added:

We expect FPH’s hospital revenues to continue growing in mid-to-high teens in FY27-FY29 which will enable the company to deliver double digit group revenue growth. FPH has the fastest growth profile across our coverage and we now believe FPH has the best price to earnings growth ratio across our coverage.

RBC has a price target of $52 on Fisher & Paykel shares.

Nanosonics Ltd (ASX: NAN)

RBC said Nanosonics had a mixed result with revenues missing expectations but earnings beating.

The broker said the Trophon business was growing and profitable, and they believed the share price was currently too bearish.

RBC has a price target of $3.75 on Nanosonics shares.

The broker also has an outperform rating on Integral Diagnostics Ltd (ASX: IDX) with a price target of $3.20.

The post CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded appeared first on The Motley Fool Australia.

More reading

• Santos, Ramsay Health Care, and AMP shares reach new 52-week highs: Can they keep climbing?
• Two broker upgrades put CSL shares back in focus
• How to make $26,000 of passive income from ASX shares
• Worried about a downturn? 3 ASX shares and 3 ETFs built to weather it
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Cameron England has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Nanosonics, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

At the end of August, Xero Ltd (ASX: XRO) shares were trading above $88. Today, you can pick them up 25% cheaper for $66.34. Xero shares have lost 17% in a month, 42% year to date, and collapsed 59% over 12 months.

For a tech stock once treated as an ASX growth darling, this is a stunning fall from grace.

A beating with no obvious trigger

Here’s the strange part: there hasn’t been a fresh earnings downgrade or a bombshell announcement behind this month’s slide of Xero shares. The company’s latest updates have mostly been routine substantial shareholder notices, and its FY26 result, released back in May, was actually pretty solid.

Revenue rose 31% to NZ$2.75 billion. Annualised monthly recurring revenue climbed 37% to NZ$3.27 billion. Subscribers grew 11% to 4.92 million. On the surface, this doesn’t look like a business in trouble.

So what’s spooking investors?

The market isn’t looking at the top line, it’s fixated on the risks underneath. Melio integration costs helped drag net profit down 27% to NZ$167.4 million, while gross margin slipped from 89% to 83.9%.

Add in broader questions about what AI could mean for software incumbents, plus lingering worries that elevated interest rates will keep punishing growth stocks, and you have a sell-off with plenty of narrative but not much hard news.

The growth case is still very much alive

Strip away the noise, and Xero added 506,000 customers over the year, lifting its global base to 4.92 million. Management isn’t backing off either — FY27 guidance points to revenue of NZ$3.62 billion to NZ$3.73 billion, implying roughly 30% growth at the midpoint.

Xero’s roots are in Australia and New Zealand, but the UK has grown into a genuine second pillar. Even so, the company reckons its total addressable market sits at around 100 million small and medium-sized businesses worldwide, a number that dwarfs its current customer base.

That’s where the US comes in. Xero finished FY26 with roughly 424,000 US customers, a fraction of what’s on the table in one of management’s three priority markets.

The Melio acquisition has strengthened Xero’s US proposition by letting businesses manage outgoing payments directly through the platform, and management pegs the US small-business payments opportunity alone at US$29 billion.

If Xero can even chip away at that, the current profit dip starts to look like the cost of buying future growth rather than a red flag.

What are brokers saying?

Opinion is split, but the tone is more optimistic than the share price suggests. Citi has a buy rating on Xero shares with a $113.60 target — nearly 70% above the current price. Morgan Stanley sees $130, and UBS is at $127.

Ord Minnett and Morgans sit more conservatively at $110 and $111. On the cautious end, RBC Capital and Jefferies have targets of $85 and $77 respectively. That’s still above where the stock trades today.

Foolish takeaway

Not a single broker target for Xero shares sits below the current share price. That’s a striking signal for a stock that’s lost more than half its value in a year. The growth numbers, the US opportunity, and now the broker consensus all point the same direction — even if the market hasn’t caught up yet.

The post Xero shares crashed 59%. What do brokers see next? appeared first on The Motley Fool Australia.

More reading

• How to make $26,000 of passive income from ASX shares
• WiseTech Global vs Xero: Which fallen ASX tech share is the better buy today?
• 3 ASX 200 shares I’d buy if I couldn’t sell for 10 years
• Down 13% in a week: Is the Xero share price finally cheap enough to buy?
• Down 54% in a year, are Xero shares now a buy, hold, or sell?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.